Telemedicine Preexposure Prophylaxis Prescribing From a Large Online US Company.

ABSTRACT:

Importance

HIV preexposure prophylaxis (PrEP) is highly effective in HIV prevention; telemedicine is a promising avenue for delivering PrEP care.

Objective

To explore telemedicine delivery of PrEP care (telePrEP) by the largest telePrEP company in the US.

Design, setting, and participants

This retrospective, single-arm cohort study used health record data of patients receiving telePrEP from MISTR LLC, a for-profit telehealth company, from November 27, 2018, to March 5, 2025. Patient characteristics and AIDSVu data were assessed to determine levels of PrEP use nationally. Retention in care was assessed for persons initiating PrEP in 2020, 2021, and 2022. Data were analyzed from March 5 to May 29, 2025.

Exposure

Use of telePrEP.

Main outcomes and measures

SUBMITTER: Siegler AJ 

PROVIDER: S-EPMC12670195 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature